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Background/Aims: The aims of this study were to evalu-
ate the effect of antiviral therapy on serum total cholesterol 
(TC) levels and to investigate the factors related to serum TC 
changes in chronic hepatitis C (CHC) patients. Methods: A 
total of 94 CHC patients, the majority of whom were infected 
with genotype 1 or 2 and were receiving antiviral therapy, 
were consecutively enrolled. TC levels before treatment, at 
week 4, at the end of treatment (EOT), and at 24 weeks after 
the EOT were analyzed, along with factors related to pre- and 
post-treatment TC levels. Results: Pretreatment TC levels in 
the sustained virologic response (SVR) group (167±3.6 mg/
dL) and the non-SVR group (158±8.3 mg/dL) were similar, 
and both decreased during antiviral therapy. The TC levels 
at 24 weeks after the EOT significantly increased in the 
SVR group (183±4.7 mg/dL), but not in the non-SVR group 
(160±7.1 mg/dL, p=0.044) after adjusting for the pretreat-
ment TC levels. The grade of hepatic ﬁ  brosis, as measured 
by the METAVIR score or the aspartate aminotransferase-
platelet ratio index (APRI), but not viral load (p=0.119), was 
an independent variable associated with the pretreatment 
TC levels (METAVIR score, p=0.011; APRI, p=0.033). After ad-
justing for the presence of a SVR by longitudinal data analy-
sis using generalized estimating equations, the independent 
variable APRI was associated with the serum TC level after 
antiviral therapy (p=0.014), whereas a SVR was associated 
with the serum TC level only with marginal statistical signiﬁ  -
cance (p=0.084). Conclusions: Serum TC levels increased in 
the SVR group after antiviral therapy for CHC; however, this 
was probably due to an improvement in liver ﬁ  brosis rather 
than the eradication of virus. (Gut Liver 2011;5:356-362)
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INTRODUCTION
Because the liver plays a fundamental role in lipid metabo-
lism, serum total cholesterol (TC) level decreases among patients 
with chronic liver disease as severity of liver disease increases.
1,2 
Chronic hepatitis C virus (HCV) infection induces more remark-
able decrease of TC and lipoprotein levels when compared to 
other types of liver disease, even in the early stage of HCV 
infection, prior to development of liver cirrhosis.
3-6 Many in-
vestigators have documented the direct effects of HCV on lipid 
metabolism.
6-9 Among patients infected with genotype 3, low 
TC level correlated with high HCV ribonucleic acid (RNA) level 
and a high degree of hepatic steatosis.
10 Moreover, hypocho-
lesterolemia was reversed after antiviral therapy in sustained 
virologic responders infected with genotype 3 HCV,
11 and high 
TC levels prior to antiviral therapy may indicate good treatment 
outcomes.
12
However, a study of the effect of HCV infection or of antivi-
ral therapy on cholesterol metabolism has been limited in areas 
where genotype 1 or 2 is prevalent, such as in the Asia-Pacific 
area.
13-15 In addition, clinical factors correlated with pretreat-
ment serum TC levels in chronic hepatitis C (CHC) and predic-
tors of change of TC levels after antiviral therapy have not been 
clearly elucidated, particularly in non-3 genotype infection.
The aims of this study were to evaluate the effect of antiviral 
therapy on serum TC level according to antiviral response, and 
to investigate factors related to pretreatment and post-treatment 
TC levels in CHC patients. 
MATERIALS AND METHODS
1. Patients 
A total of 94 CHC patients treated with interferon (IFN)-α, Jang ES, et al: Cholesterol Level in Chronic Hepatitis C  357
pegylated IFN α-2a, or α-2b combined with ribavirin and 
completely evaluated for virologic response were consecutively 
enrolled at Seoul National University Bundang Hospital be-
tween October 2003 and October 2008. CHC was defined by 
detectable serum anti-HCV antibodies, as well as HCV RNA for 
more than 6 months. Exclusion criteria included chronic liver 
disease caused by other than HCV (i.e., hepatitis B viral hepati-
tis, nonalcoholic steatohepatitis, alcoholic liver disease, autoim-
mune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, 
Wilson’s disease), human immunodeficiency virus infection, or 
hepatocellular carcinoma.
2. Methods
Retrospective review of electronic medical records and me-
ticulous data collection were performed. The study protocol was 
approved by the Institutional Review Board of Seoul National 
University Bundang Hospital. 
Presence of liver cirrhosis was evaluated by ultrasonography, 
computed tomography, and/or liver biopsy. Among the total 
of 94 patients, 60 cases underwent liver biopsy; slides were re-
viewed by an experienced liver pathologist who was blinded to 
the clinical course, according to the METAVIR scoring system.
16 
As a simple and validated serum marker of hepatic fibrosis, as-




Treatment responses were defined as early virologic response 
(EVR), a decrease of more than 2 log10 serum HCV RNA at week 
12 of treatment, and end-of-treatment response (ETR), unde-
tectable serum HCV RNA at week 24 (for genotype 2 or 3) or 
at week 48 (for genotype 1 or 4) of antiviral therapy. Sustained 
virologic response (SVR) was defined as continued undetectable 
HCV RNA at 24 weeks after end-of treatment (EOT). Serum TC, 
alanine aminotransferase, albumin, and APRI were recorded 
at pretreatment, week 4 of treatment, EOT, and 24 weeks after 
Table 1. Comparison of the Clinical Characteristics of the Sustained Viral Response (SVR) Group and the Non-SVR Group after Antiviral Therapy 
for Chronic Hepatitis C
Characteristic Overall (n=94) SVR (+) (n=72) SVR (-) (n=22) p-value
Age, yr   53.4±11.2   52.6±11.3   55.9±10.9 0.226
Male, n (%) 52 (55.3) 45 (62.5)   7 (31.8) 0.011
BMI, kg/m
2 24.0±2.7 23.9±2.7 24.1±2.6 0.866
Liver cirrhosis, n (%) 23 (24.5) 13 (18.1) 10 (45.5) 0.009
Pathology 
  Fibrosis, Grade 3/4, n/N (%) 15/60 (25.0) 11/45 (24.4) 4/15 (26.7) 1.000
Laboratory findings
  Platelet, ×10
3/μL 173.0±81.0 181.6±83.8 144.7±64.8 0.062
  Total cholesterol, mg/dL 164.8±32.9 166.8±30.9 158.3±39.0 0.290
  Albumin, g/dL   4.1±0.3   4.1±0.3   4.0±0.4 0.086
  ALT, IU/L 112.2±93.9   118.3±100.3   92.2±67.0 0.257
  Prothrombin time, INR   1.07±0.12   1.06±0.11   1.12±0.13 0.050
  Genotype 1, n (%) 38 (40.4) 26 (36.1) 12 (54.5) 0.123
  HCV RNA, log IU/mL   5.5±0.8   5.4±0.8   5.9±0.5 0.049
  APRI   1.4±1.1   1.4±1.2   1.5±1.1 0.719
Treatment
  Type 0.782
    PegIFN α-2a, n (%) 25 (26.6) 20 (27.8)   5 (22.7)
    PegIFN α-2b, n (%) 41 (43.6) 30 (41.7) 11 (50.0)
    Conventional IFN, n (%) 28 (29.8) 22 (30.6)   6 (27.3)
  Completion, n (%) 71 (75.5) 60 (83.3) 11 (50.0) 0.001
  Responses
    RVR (n=46), n (%) 28 (60.9) 24 (64.9)   4 (44.4) 0.284
    EVR (n=86), n (%)  79 (91.9) 65 (98.5) 14 (70.0) <0.001
    ETR (n=89), n (%)  76 (85.4) 63 (92.6) 13 (61.9) 0.002
All results for continuous variables are shown as mean±SD.
BMI, body mass index; ALT, alanine aminotransferase; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, aspartate aminotransferase-platelet 
ratio index; PegIFN, pegylated interferon; IFN, interferon; RVR, rapid virologic response; EVR, early virologic response; ETR, end of treatment re-
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EOT. 
3. Statistical analysis
Student’s t-tests and Mann-Whitney U-tests for continuous 
variables, χ
2 and Fisher’s exact tests for categorical variables 
were used for univariate analysis in the search for predictors 
of SVR. Variables with p-values of <0.1 by univariate analysis 
were included in a multiple binary logistic regression model. 
The changes of serum TC level and APRI scores from pretreat-
ment to week 4 of treatment, EOT, and 24 weeks after EOT were 
analyzed by repeated measures analysis of variance (ANOVA). 
To determine independent effects of clinical variables associated 
with serum TC after antiviral therapy, univariable and multi-
variable generalized estimating equation (GEE) analyses were 
used with adjustment of time dependent changes of serum TC 
levels. All statistical evaluations were performed using SPSS 
version 17.0 (SPSS Inc., Chicago, IL, USA). p-values of <0.05 
were considered statistically significant. 
RESULTS
1. Clinical characteristics of patients
The mean age of the 94 eligible patients was 53 years, and 
55% were males. The major viral genotypes were 1 (41%) and 2 
(52%). Only 1 (1.1%) patient had genotype 3, and 2 (2.1%) had 
genotype 6. Among 60 liver biopsy specimens, 25% revealed 
fibrosis grade 3 or 4 using the METAVIR scoring system, and 
APRI scores showed significant correlation with grades of fibro-
sis (γ=0.549, p<0.001). Therefore, APRI score was confirmed as 
a significant indicator of fibrosis in our study. 
Twenty-three (24.5%) patients were withdrawn from antiviral 
therapy due to side effects (n=20) and lack of EVR (n=3). Of 94 
patients, 72 (76.6%) had SVR: 26 of 38 (68.4%) in genotype 
1, 46 of 56 (82.1%) in genotype non-1. Comparison of clinical 
characteristics between the SVR group and the non-SVR group 
is shown in Table 1. Pretreatment TC levels in the SVR group 
were not different from those in the non-SVR group (p=0.290, 
Table 1), while being male, having a pretreatment HCV RNA 
titer <5.5 log IU/mL, and completion of antiviral therapy were 
significant independent factors for predicting SVR in our pa-
tients by logistic regression analysis (male, odds ratio [OR] 47.2, 
95% confidence interval [CI] 2.38 to 936.76, p=0.012; pretreat-
ment HCV RNA <5.5 log IU/mL, OR 20.3, 95% CI 1.21 to 341.8, 
p=0.037; completion of antiviral therapy, OR 34.2, 95% CI 1.91 
to 611.7, p=0.016; data not shown). 
2. Changes of serum TC levels in the SVR and the non-SVR 
groups
TC levels were significantly changed during and after anti-
viral therapy (Fig. 1). Serum TC levels decreased at week 4 of 
treatment and remained at the decreased levels until EOT in 
both SVR and non-SVR groups. At 24 weeks after EOT, the SVR 
group revealed significantly increased TC levels (183±4.7 mg/dL) 
compared to pretreatment TC levels (167±3.6 mg/dL), while such 
Fig. 1. (A) Changes in serum total cholesterol (TC) levels during and after antiviral therapy in chronic hepatitis C patients. Sustained virologic 
responders (SVR group, ˙) show a significant increase in the serum TC level 24 weeks after the end-of-treatment (EOT) compared to pretreat-
ment serum TC. In contrast, there is no increase in the serum TC level 24 weeks after the EOT in the non-SVR group (˛). The changing patterns 
of serum TC levels during and after antiviral therapy are not significantly different between the SVR and non-SVR groups (*p=0.131) by repeated 
measure ANOVA. (B) Estimated change of in the serum TC levels during and after antiviral therapy in chronic hepatitis C patients after adjusting 
for the pretreatment cholesterol levels. Because the mean pretreatment cholesterol level of SVR group (˙) is higher than that of non-SVR group (˛), 
a repeated measure ANOVA is performed after adjusting for the pretreatment cholesterol level. As a result, the change in the estimated serum TC 
levels after antiviral therapy is significantly different between the SVR and non-SVR groups (p=0.044).Jang ES, et al: Cholesterol Level in Chronic Hepatitis C  359
an increase was not observed in the non-SVR group (Fig. 1A). 
The changes of TC levels during and after antiviral therapy were 
not significantly different between SVR and non-SVR group by 
repeated measure ANOVA analysis (p=0.131). However, TC level 
of SVR group was higher than non-SVR group although it was 
not significant (Table 1). Thus, we performed another repeated 
measure ANOVA after adjusting for pretreatment TC level to 
determine whether the change of TC levels from pretreatment 
to 24 weeks after EOT in SVR was different from that of non-
SVR group. As a result, estimated serum TC levels after antiviral 
therapy significantly increased in SVR group compared to non-
SVR group after adjusting for pretreatment TC (p=0.044, Fig. 
1B).
3. Clinical variables associated with pretreatment TC levels 
in CHC
As shown in Table 2, pretreatment TC levels were not associated 
with the HCV genotype or viral load. However, pretreatment serum 
TC levels declined significantly as Child-Pugh score increased or 
as platelet count decreased (Child-Pugh score, β=-21.42, 95% CI 
-35.6 to -5.25, p=0.010; platelet count, β=0.11, 95% CI 0.04 to 
0.19, p=0.004; Table 2). In addition, METAVIR grade of fibrosis 
and APRI score were found to be significantly correlated with 
pretreatment serum TC levels in CHC patients (grade of fibrosis, 
β=-10.11, 95% CI -17.8 to -2.41, p=0.011; APRI, β=-5.07, 95% 
CI -9.73 to -0.41, p=0.033; Table 2). Therefore, pretreatment TC 
levels of CHC patients showed significant negative association 
with their severity of hepatic fibrosis.
4. Clinical variables associated with the change of serum 
TC levels after antiviral therapy in CHC
As mentioned above, serum TC levels at 24 weeks after anti-
viral therapy for CHC significantly increased in the SVR group 
(Fig. 1). To evaluate independent variables associated with se-
rum TC levels after adjusting for the time-dependent changes, 
longitudinal analyses using GEE were performed. According to 
univariable analyses, serum TC level was significantly affected 
by fibrosis markers including platelet count (β=0.15, 95% CI 0.01 
to 0.29, p=0.034; Table 3), METAVIR grade (β=-9.59, 95% CI 
-16.93 to -2.25, p=0.010; Table 3), Child-Pugh score (β=-24.18, 
Table 2. Clinical Variables Associated with the Pretreatment Serum 





Age, yr -0.46 -1.00 to 0.08 0.096
Female -0.64 -13.36 to 12.09 0.921
BMI, kg/m
2 -2.11 -4.50 to 0.29 0.084
HCV RNA titer, log IU/mL   8.20 -2.14 to 18.54 0.119
Genotype 1 -1.64 -14.42 to 11.15 0.800
Platelet count, ×10
3/μL   0.11   0.04 to 0.19 0.004
METAVIR grade -10.11 -17.80 to -2.41 0.011
Child-Pugh score -21.42 -35.60 to -5.25 0.010
APRI -5.07 -9.73 to -0.41 0.033
CI, confidence interval; BMI, body mass index; HCV, hepatitis C vi-
rus; RNA, ribonucleic acid; APRI, aspartate aminotransferase-platelet 
ratio index.
Table 3. Clinical Variables Associated with the Serum Total Cholesterol Level after Antiviral Therapy Identified Using Generalized Estimating 
Equations with an Adjustment for Time-Dependent Changes in the Total Cholesterol Level
Variable







Age, yr -0.23 -0.74 to 0.29 0.390 -
Female   1.80 -11.11 to 14.70 0.785 -
BMI, kg/m
2 -1.03 -3.48 to 1.41 0.406 -
HCV RNA titer, log IU/mL   5.78 -5.54 to 17.10 0.317 -
Genotype 1 -6.23 -18.87 to 6.40 0.333 -
Platelet count, ×10
3/μL   0.15   0.01 to 0.29 0.034 -
METAVIR grade -9.59 -16.93 to -2.25 0.010 -
Child-Pugh score -24.18 -38.65 to -9.72 0.001 -
APRI -7.81 -13.85 to -1.78 0.011 -8.04   -14.43 to -1.66 0.014
SVR 14.44 -0.69 to 29.58 0.061 12.62 -1.69 to 26.94 0.084
These variables show significant correlation with serum cholesterol by univariable analyses. The significant variables in univariable analyses in-
cluding platelet count, METAVIR grade and Child-Pugh score are excluded in the multivariable model because they can be representative as APRI. 
CI, confidence interval; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, aspartate aminotransferase-platelet ratio in-
dex; SVR, sustained virologic response.
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95% CI -38.65 to -9.72, p=0.001; Table 3), and APRI (β=-7.81, 
95% CI -13.85 to -1.78, p=0.011; Table 3). Moreover, APRI was 
an independent factor associated with serum TC levels by the 
multivariable GEE analysis (β=-8.04, 95% CI -14.43 to -1.66, 
p=0.014; Table 3). In this multivariable model, the eradication of 
viruses (SVR) was also included because it was associated with 
serum TC levels with p-value of less than 0.1. 
The changes of APRI during and after antiviral therapy for 
CHC were different from SVR and non-SVR group (p=0.05, Fig. 
2A). At 24 weeks after EOT, SVR group revealed significantly 
decreased APRI (0.46±0.06) compared to the pretreatment APRI 
(1.36±0.14). The changes of APRI were different more signifi-
cantly between SVR and non-SVR groups after adjusting for 
pretreatment APRI (p<0.001, Fig. 2B). Therefore, the APRI con-
tinuously decreased during and after antiviral therapy, while 
serum TC levels decreased during antiviral therapy and then 
increased after EOT in SVR group. 
DISCUSSION 
In the present study, serum TC level significantly increased at 
24 weeks after EOT among those in SVR group after antiviral 
therapy for CHC, but not in non-SVR group. Pretreatment and 
post-treatment TC levels were both independently associated 
with grade of hepatic fibrosis, while achievement of SVR was 
marginally associated with post-treatment TC levels. These re-
sults suggest that the change of serum TC levels according to 
antiviral therapy may be caused by improvement of hepatic 
fibrosis secondary to viral eradication rather than by the elimi-
nation of direct effects of HCV to the cholesterol metabolism in 
infected hepatocytes. 
Serum TC level represents total amount of endogeneously 
synthesized and exogeneously absorbed cholesterols, which are 
transported into blood by binding to lipoproteins including very 
low density lipoprotein (VLDL), low density lipoprotein (LDL), 
and apolipoproteins. Endogenous cholesterol is synthesized in 
hepatocytes via the mevalonate pathway.
9,21 On the other hand, 
exogenous cholesterol is endocytosed as the form of cholester-
ylester of LDL in hepatocytes and hydrolyzed to free cholesterol 
and fatty acid.
22 Because most of these metabolic processes of 
lipid occur in the liver, serum TC level is closely related to the 
severity of liver diseases.
1,2
Meanwhile, HCV has been documented to be able to inter-
rupt lipid metabolism directly. HCV binds to LDL receptors in 
the membrane of hepatocytes for entry into the cells,
7 and HCV 
particles are released from hepatocytes via VLDL secretion path-
way.
7,9,23 Moreover, HCV requires geranylgeranyl-pyrophosphate 
(PP) in the mevalonate pathway for replication, which may 
result in hypocholesterolemia, because HCV-infected cells spend 
most of the mevalonate as a substrate for geranylgeranyl-PP, 
rather than synthesis of cholesterol.
22,24 Besides inhibition of 
cholesterol synthesis, HCV could impede cholesterol secretion 
into blood via the VLDL secretion pathway.
23,25 These findings 
suggest that HCV itself may play a role to induce hypocholes-
terolemia independent of hepatic fibrosis, however, it has not 
been confirmed in human. 
Fig. 2. (A) Change in the aspartate aminotransferase-platelet ratio index (APRI) during and after antiviral therapy for chronic hepatitis C patients. The 
APRI score improves in the sustained virologic response (SVR) group (˙, p<0.001), but not in the non-SVR group (˛, p=0.199). The changing APRI 
pattern during and after antiviral therapy is significantly different between the SVR and non-SVR groups (*p=0.05; repeated measure ANOVA). (B) 
Estimated change in the APRI level during and after antiviral therapy in chronic hepatitis C patients after adjusting for the pretreatment APRI. The 
change in the estimated APRI during and after antiviral therapy is significantly different between the SVR and non-SVR groups (*p<0.001). 
EOT, end-of-treatment.Jang ES, et al: Cholesterol Level in Chronic Hepatitis C  361
Many investigators have reported that reversals of hypo-
cholesterolemia after antiviral therapy for CHC were observed 
among patient infected with HCV genotype 3, but there have 
been limited studies on the change of total cholesterol levels 
during and after antiviral therapy in genotype 1 and 2 infec-
tions.
11,13,14,26 For the changing pattern of TC levels during 
antiviral therapy for genotype non-3 CHC, some studies have 
shown gradual increase of TC levels,
11,13 while other studies
14,27 
have shown decrease of TC levels which was compatible with 
our results. The present study clearly showed that SVR resulted 
in reversal of hypocholesterolemia in patient infected mostly 
with genotype non-3 (98.9%). 
On the other hands, the mechanism of reversal of hypocho-
lesterolemia in HCV genotype non-3 infection can be differ-
ent from that in genotype 3 infection. Thus, we hypothesized 
that the serum TC levels may increase after successful antiviral 
therapy by either eradication of HCV (SVR) or improvement of 
hepatic fibrosis which follows after viral eradication. To search 
the underlying reason for the increase of TC levels after SVR, 
we searched clinical variables associated with serum TC level, 
at pretreatment and post-treatment. Consequently, pretreatment 
TC level was inversely correlated with severity of liver fibrosis 
indicated as platelet count, METAVIR grade, Child-Pugh score 
and APRI. Although pretreatment TC level did not predict SVR 
in patients with genotype 1 or 2 infection, the elimination of 
hepatitis viruses from the liver was associated with the improve-
ment of fibrosis grade and APRI. Those findings have not yet 
been sufficiently reported. 
In addition, APRI scores decreased significantly in the SVR 
group than those in non-SVR group during and after antiviral 
therapy. As APRI is a simple and valid serum fibrosis marker,
20,28 
rapid reduction of APRI score may reflect a remarkably dynamic 
process related to improvement of liver fibrosis and inflamma-
tion during antiviral therapy. According to the multivariable 
analysis, APRI was the independent variable associated with the 
change of serum TC level after antiviral therapy. On the other 
hands, the viral eradication as indicated as SVR showed a mar-
ginal association with the change of TC levels. Therefore, the 
reversal of hypocholesterolemia in genotype 1 and 2 infected 
CHC after successful antiviral therapy may be mainly caused 
by improvement of hepatic fibrosis secondary to eradication of 
viruses rather than by direct effect of HCV eradication on cho-
lesterol mechanism in CHC. However, further large prospective 
study is warranted to distinguish which factor plays the domi-
nant role in increase of serum TC level after achieving SVR. 
Among many other factors affecting serum cholesterol levels, 
such as race, age, gender, diabetes, and body mass index (BMI),
29 
BMI is one of the important determinants.
30,31 Therefore, de-
creasing pattern of TC level during the antiviral therapy in our 
results is probably related to the decreased dietary intake and 
loss of body weight due to anorexia and other adverse effects 
of the therapy. However, age and BMI which were expected to 
affect serum TC levels significantly showed p-value less than 0.1 
as the correlation analysis, probably due to small sample size.
The limitations of this study included retrospective design, 
relatively small sample size, and single center experience. The 
subgroup profiles of serum TC, which include LDL, VLDL, and 
high density lipoprotein, along with fasting glucose level were 
not available in the most of our subject patients due to retro-
spective design. We could not extensively investigate factors 
related to exogenous cholesterol uptake, such as dietary intake 
or body weight change during the course of antiviral therapy. 
In conclusion, serum TC levels increased in the SVR group 
after antiviral therapy for CHC. The change may be explained 
by the improvement of liver fibrosis rather than by the eradica-
tion of HCV per se. Further investigation is needed to elucidate 
molecular mechanisms for the reversal of hypocholesterolemia 
in sustained viral responders, especially under the consideration 
of the change of hepatic fibrosis.
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